Melanotan 2 FAQ — Research Questions Answered from the Published Literature

Melanotan 2 (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Developed at the University of Arizona, it was designed to be more potent and metabolically stable than native alpha-MSH. Its full sequence is Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH2. It binds MC1R, MC3R, MC4R, and MC5R and has been studied primarily for melanogenesis stimulation, erectile function, and appetite modulation.^[1][18]

In the Dorr 1996 Phase I study, five subcutaneous doses over ten days produced measurable reflectance-based pigmentation increases within 2–3 weeks.^[1] Individual response varied with baseline Fitzpatrick skin type. Exact timelines were not formally characterized in the three-subject pilot.

A 2020 case report documented right-sided renal infarction affecting approximately 50% of kidney tissue in a patient after self-administering 27 mg of MT-II subcutaneously over six months.^[4] The proposed mechanisms include thrombotic pharmacological influence and direct nephrotoxic effect. This was the first published renal infarction case in the Swedish Poison Center's record of 215 MT-II exposures.

No peer-reviewed study has demonstrated MT-II lowering testosterone in humans. Raposinho 2003 documented in rats that central MT-II infusion counteracted NPY-driven hyperphagia but did not affect LH pulsatility, suggesting the gonadotropic axis operates independently of melanocortinergic feeding modulation.^[14] Direct testosterone suppression has not been a reported finding in published human or animal MT-II literature.

MC1R activation can in principle stimulate melanin synthesis in hair follicle melanocytes. Case reports and user forum observations mention hair darkening following MT-II use.^[7] No controlled human study measuring hair pigmentation as an endpoint has been published. The effect is biologically plausible but not formally characterized in the research record.

MC4R agonism by MT-II reduces food intake in rodent models, and chronic central melanocortin activation produces persistent body mass reduction. Cote 2017 documented that 40-day central melanocortin activation in rats reduced intra-abdominal fat by 35–55% and produced 3-fold elevation in brown adipose tissue thermogenesis, even after food intake returned to baseline.^[5] Tolerance to the anorexic effect developed within 5 days; the thermogenic effect persisted.

Central melanocortin receptor signaling interacts with dopaminergic and oxytocinergic pathways. Thurston 2022 demonstrated in a 31-subject randomized trial that MC4R agonism enhanced amygdala-insula connectivity during erotic stimuli.^[11] Paiva 2017 documented increased oxytocin neuron firing rates following IV MT-II in rats.^[15] Direct dopamine measurement data for human MT-II administration are not published.

There is no peer-reviewed evidence that MT-II changes iris color. Iris color is genetically determined by melanocyte number and melanin content across the iris stroma; adult iris color change is not a documented outcome in any published MT-II trial or case series. User-reported observations of iris color change lack controlled study validation.

Transient effects — nausea, flushing, spontaneous erections — emerged within 30–60 minutes of subcutaneous injection in the Dorr 1996 human trial.^[1] Pigmentation changes were measurable at 2–3 weeks. The plasma half-life is approximately 1 hour based on available pharmacokinetic data^[16]; melanogenic effects persist far longer because eumelanin is deposited in skin cells that remain long after peptide clearance.

MT-I (afamelanotide) is a linear 13-amino-acid alpha-MSH analog that is primarily MC1R-selective. MT-II is a cyclic 7-amino-acid analog that activates MC1R, MC3R, MC4R, and MC5R. Afamelanotide received EMA approval for erythropoietic protoporphyria; MT-II remains unapproved globally. The clinical program most directly derived from MT-II is bremelanotide (PT-141), a cyclic metabolite that received FDA approval in 2019 for HSDD.

MT-II is not approved by any regulatory authority. Published case reports document renal infarction^[4], histologically confirmed melanoma^[9], dysplastic nevus transformation^[8][20], and ischemic priapism requiring surgery.^[10] Regulatory agencies including TGA and MHRA have issued enforcement warnings.

MT-II binds MC1R (pigmentation), MC3R (energy homeostasis), MC4R (sexual function, appetite, autonomic tone), and MC5R (exocrine gland function). It is a non-selective melanocortin agonist; MC4R agonism drives the central effects (erectile response, appetite suppression) documented in the Wessells^[2][3] and Cote^[5] studies.

Plasma half-life is approximately 1 hour based on rat IV pharmacokinetic data (Ugwu 1994).^[16] MT-II's cyclic structure confers approximately 4–6-fold greater metabolic stability than linear alpha-MSH (~10–15 min). Melanogenic effects persist far longer than plasma presence, because eumelanin already deposited in skin remains through normal cellular turnover.

Published research has studied Melanotan 2 for melanogenesis stimulation (UV-independent tanning)^[1], erectile dysfunction via MC4R^[2][3], appetite modulation via central melanocortin circuits^[5][6], neuroprotection in peripheral nerve injury^[13], and insulin sensitivity in rodent models. None have reached regulatory approval for MT-II.

Published research protocols describe reconstitution of lyophilized MT-II in sterile water or bacteriostatic saline. Specific preparation details should be drawn from the methodology sections of published studies. Oral bioavailability in rats is 4.6%^[16], which is why parenteral routes are used in all clinical-stage human research.